Press releases
- Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
- Newron Presents 2023 Financial Results and Provides 2024 Outlook
- Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
Key statistics
On Thursday, Newron Pharmaceuticals SpA (NP5X:GER) closed at 6.90, 80.63% above the 52 week low of 3.82 set on Jun 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.36 |
---|---|
High | 7.36 |
Low | 6.90 |
Bid | 6.90 |
Offer | 7.10 |
Previous close | 7.40 |
Average volume | 4.68k |
---|---|
Shares outstanding | 18.63m |
Free float | 17.16m |
P/E (TTM) | -- |
Market cap | 135.46m CHF |
EPS (TTM) | -0.8834 CHF |
Data delayed at least 15 minutes, as of Apr 18 2024 16:35 BST.
More ▼